ClinConnect ClinConnect Logo
Search / Trial NCT05193149

Inspiratory Muscle Training in Obese Breast Cancer Survivors

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Dec 31, 2021

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how inspiratory muscle training can help improve exercise tolerance for obese women who have survived breast cancer. Specifically, it's aimed at women who have completed their active treatment for stage 0 to stage III breast cancer within the last 6 months to 5 years and have a body mass index (BMI) between 30 and 50. Participants should be generally inactive, meaning they engage in less than 90 minutes of moderate exercise each week and experience some limitations in physical activity.

Eligible participants can expect to take part in a structured training program designed to strengthen their breathing muscles, which may help them feel more comfortable and capable during physical activities. It's important to note that women who have serious heart issues, current infections, certain psychiatric conditions, or who smoke will not be able to participate. This study is currently recruiting and aims to support breast cancer survivors in improving their overall fitness and quality of life.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • completed active treatment for a Stage 0-III breast cancer diagnosis within 6 months to 5 years of enrollment.
  • obese as defined by a body mass index (BMI) of 30 to 50 kg/m2
  • patients who are on adjuvant endocrine therapy will be allowed to participate.
  • sedentary (participating in less than 90 min of moderate intensity activity per week) and have at least one limitation in activity on the 10-question RAND-36 Physical Function Subscale to ensure some exercise intolerance
  • Exclusion Criteria:
  • functional limitations that make independent exercise unsafe
  • metastatic breast cancer
  • ongoing or active infection with recent antibiotics or steroids
  • Bilateral Axillary lymph node dissection (ALND) of \>5 lymph nodes on each side, which could increase risk of lymphadenopathy with repeated blood pressure measurements during exercise or if patient has been advised by their clinician to avoid repeated BP measures on both arms. Bilateral Sentinel Lymph Node Biopsy (SLNB) will be allowed.
  • heart disease precluding exercise (congestive heart failure, unstable angina pectoris, cardiac arrhythmia)
  • psychiatric illness/social situations that would limit compliance with study requirements
  • orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise
  • unwilling or unable to follow protocol requirements
  • pregnant or nursing
  • any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study
  • presence of provokable ECG changes suggestive of heart disease, or dangerous arrhythmias or exercise induced hypertension, etc. during the cardiopulmonary exercise test
  • non-English speaking

About Ohio State University Comprehensive Cancer Center

The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.

Locations

Columbus, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Dharini M Bhammar, PhD

Principal Investigator

Ohio State University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials